Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
Said, Rabih
Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. [electronic resource] - Expert opinion on biological therapy 11 2017 - 1463-1470 p. digital
Publication Type: Journal Article
1744-7682
10.1080/14712598.2017.1377178 doi
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized--adverse effects
Antigens, CD20--immunology
Antineoplastic Agents, Alkylating--therapeutic use
Antineoplastic Agents, Immunological--adverse effects
Clinical Trials as Topic
Drug Therapy, Combination
Half-Life
Humans
Leukemia, B-Cell--drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy
Neutropenia--etiology
Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. [electronic resource] - Expert opinion on biological therapy 11 2017 - 1463-1470 p. digital
Publication Type: Journal Article
1744-7682
10.1080/14712598.2017.1377178 doi
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized--adverse effects
Antigens, CD20--immunology
Antineoplastic Agents, Alkylating--therapeutic use
Antineoplastic Agents, Immunological--adverse effects
Clinical Trials as Topic
Drug Therapy, Combination
Half-Life
Humans
Leukemia, B-Cell--drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy
Neutropenia--etiology